Streetbeat News

Stock Prices

BMEA

Biomea Fusion (NASDAQ:BMEA) reported Q2 losses of $(1.03) per share, beating the analyst consensus estimate of $(1.07) by 3.74%. This represents a 47.14% increase in losses compared to $(0.70) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:09 pm

OCGN

Ocugen shares are trading lower following the company's announcement of an underwritten public offering.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:08 pm

OCGN

Ocugen has announced an underwritten public offering of its common stock, though the size of the offering has not been disclosed. The underwriter has been granted a 30-day option to purchase an additional 15% of shares. The offering is subject to market and other conditions.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:08 pm

MDXG

MiMedx Group shares are trading lower after the company reported worse-than-expected Q2 sales results.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:07 pm

CTNM

Contineum Therapeutics (NASDAQ:CTNM) announced the publication of preclinical data on PIPE-307, a selective M1 receptor inhibitor for relapse-remitting multiple sclerosis, in the Proceedings of the National Academy of Sciences. The data suggest PIPE-307 could be a first-in-class treatment.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:07 pm

SDGR

Schrodinger shares are trading higher after the company reported better-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:06 pm

XAIR

Beyond Air has announced the publication of a scientific article on the safety evaluation of high-dose inhaled nitric oxide in COVID-19 viral pneumonia in Scientific Reports, an online journal by Nature Publishers.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:05 pm

NRDS

NerdWallet shares are trading lower after the company reported mixed Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:05 pm

INVA

Innoviva (NASDAQ:INVA) reported a Q2 EPS of $(0.55), missing the $0.23 estimate by 339.13%, and a 2850% decrease from last year's $0.02 EPS. However, sales were $99.90M, beating the $74.69M estimate by 33.75% and increasing 23.34% from last year's $80.99M.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:05 pm

EXAS

Exact Sciences shares are trading higher after the company reported better-than-expected Q2 financial results and announced an exclusive license agreement with TwinStrand Biosciences.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:05 pm